DOCSLIB.ORG

The Cardiac Patient

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Advanced Cardiovascular Pharmacology Update JOHN SHIELDS, DNP, CRNA Systemic Circulation BP=CO x SVR CO dependent on o Stroke volume o Preload o Contractility o Afterload o Heart rate Vascular tone Blood viscosity Pulmonary Circulation Pulmonary vessels are very thin-walled o Pulmonary circulation resembles venous capacitance vessels o Diversion of blood from one region to another is facilitated ▪ Recruitment ▪ Distension ▪ HPV RV function is very afterload dependent Biventricular Circulation Management LV failure managed differently than RV failure LV is a stupid pump o Inotropes o Volume manipulation via Frank- Starling Curve o Ohm’s Law RV is a bellows that responds best to contractility drugs and afterload reduction o Inodilators o Ventilation Drugs Used to Treat Low Systemic Cardiac Output/Hypotension Vasopressors Alpha-adrenergic drugs Mixed agonists Vasopressin Methylene blue Other Inotropes Beta-adrenergic drugs Mixed agonists PDE III Digitalis Calcium Glucagon Triiodothyronine Levosimendan Other Alpha-Adrenergic Receptor Pharmacology Alpha-1 activation results in increased calcium and contraction of vascular smooth muscle (IP3) Effects include vasoconstriction, intestinal relaxation, pupillary dilation Theory evolving regarding multiple alpha receptors Beta-Adrenergic Receptor Pharmacology Beta-1 activation results in chronotropic and inotropic effects (cAMP) Counterpart to vagal system via SNS Beta-2 activation affects vascular and pulmonary smooth muscle Vasopressin Receptor Pharmacology V1 receptor activation results in IP3 signal pathway and contraction of vascular smooth muscle Effects include vasoconstriction, similar to alpha with weak inotropic effect Side effects include myocardial ischemia and reduction in splanchnic blood flow Dopamine Receptor Pharmacology Unique in ability to simultaneously increase o Myocardial contractility o Renal/mesenteric blood flow o GFR, excretion of sodium o UOP Dose-dependent pharmacodynamics and effect on cAMP and Ca++ PDE-3 Receptor Pharmacology cAMP increases contractility PDE3 breaks down cAMP to AMP Inhibition of PDE3 increases cAMP levels and increases o Contractility (inotropy) o Heart rate (chronotropy) o Conduction velocity (dromotropy) Calcium Receptor Pharmacology Changes in force of contraction and SVR result from incremental degrees of binding between myosin and actin Degree of binding depends on calcium ion concentration in the cell Catecholamines affect the concentration of calcium in the cell Muscarinic Receptor Pharmacology Parasympathetic blockade or activation can mediate SA node firing and resting membrane potential Parasympathetic receptor activation can influence IP3, cAMP and nitric oxide release Muscarinic receptor blockade increases cardiac norepinephrine spillover when HF is not present Blunting of parasympathetic influence on sympathetic activity is present in HF Dysrhythmia Pharmacology Dysrhythmias may be due to disturbances in automaticity, Tachyarrhythmias conduction and/or re-entry Enhanced Re-Entry Etiology may be mechanical, Automaticity reflex, pharmacologic, Altered Altered Impulse Impulse disease, ion channel or Formation Conduction adrenergic Decreased Conduction Automaticity Blocks Treatment should target action potential and Bradyarrhythmias automaticity Phenylephrine Sympathomimetic amine, direct alpha agonist, (?) mild beta agonist Indicated for hypotension with low-normal CO o Useful in counteracting decrease in SVR from anesthetic agents o Useful for drop in SVR from spinal and epidural blocks Useful in patients with ischemic heart disease (no inotropic or chronotropic effects) Ephedrine Mild indirect alpha agonist, direct beta agonist (causes release of NE from neurons) Indicated for hypotension with low CO and low HR Efficacy is blunted when NE stores are low, tachyphylaxis (>150 mg) CV effects of ephedrine resemble those of epi, but BP ↑ is less intense and lasts about 10x longer Vasopressin Produces direct peripheral vasoconstriction via V1 receptors Acts independently of adrenergic receptors o Useful in refractory hypotension in sepsis, patients taking ACE inhibitors o Useful for hypotension refractory to phenylephrine or ephedrine o More effective than alpha or beta in vasoplegic/acidotic state Minimal decrease in pulmonary vascular resistance Dose is 0.5-2 mcg bolus, infusion 0.04 mcg/minute Calcium Increases inotropy without increase in HR Increases SVR and PVR in dose dependent fashion Reverses hypotension due to volatile, CCB’s, hypocalcemia, Mg, K+ Provokes digitalis toxicity Promotes coronary spasm and pulmonary hypertension Anticholinergic Drugs Block inhibitory effects of the parasympathetic neurotransmitter acetylcholine on heart rate leading to tachycardia Atropine inhibits acetylcholine- induced decreases in cAMP by acting as an allosteric PDE type 4 (PDE4) inhibitor o Increase in HR o Increase in contractility Glycopyrrolate increases heart rate but has no real effect on contractility Ruwan et al. Atropine augments cardiac contractility by inhibiting cAMP-specific phosphodiesterase type 4Sci Rep. 2017; 7: 15222 Norepinephrine Potent α1-adrenergic receptor agonist with β-agonist activity almost equal to epinephrine, no beta 2 Powerful vasoconstrictor with less potent direct inotropic properties o Used for hypotension refractory to phenylephrine o Used for heart failure in ischemic heart disease o Used in sepsis/vasoplegia May confer risk of ischemia of bowel and kidneys at higher doses Bolus 3-12 mcg/infusion rate 2-30 mcg/minute Epinephrine Increases cardiac inotropy and chronotropy, but alpha effects predominate at higher doses o 0.003-0.02 mcg/kg IV for refractory hypotension/CHF (10-20 mcg) o Infusion start at 2 mcg/minute for CO, up to 5 mcg/minute for hypotension/CHF Very effective bronchodilator but also enhances gluconeogenesis and elevated lactate Tachycardia, dysrhythmias and lactate are dose limiting effects Dobutamine Direct beta-1 adrenergic agonist, limited beta-2 and alpha-1 Higher safety index than epinephrine Very mild vasodilation, no effect on glucose Increases CO with less of an increase in MVO2 and heart rate Low cardiac output states, especially with high SVR or PVR Excellent drug for right ventricular failure Dose as infusion is 2-20 mcg/kg/min Dopamine Receptor Pharmacology Direct alpha 1, beta 1, beta 2 and dopaminergic (DA1) Indirect release of stored neuronal NE Dose response relationship between DA1, beta-1 and alpha-1 0.5 – 2 g/kg/min renal vasodilation, ↑ GFR and Na++ excretion (dopamine 1 receptors) 2 – 10 g/kg/min beta1 agonism cardiac contractility and output are increased (beta 1 receptors) > 10 g/kg/min alpha1 and beta1agonism, alpha-adrenergic vasoconstriction and benefit to renal perfusion may be lost Digitalis Positive inotropic effect but minor compared to catecholamines and others Digitalis works by inhibiting sodium-potassium ATPase, and increases calcium availability by increasing intracellular sodium (less extrusion of calcium) Therapeutic effects develop at approximately 35% and dysrhythmias typically manifest at approximately 60% of the fatal dose Methylene Blue for Vasoplegia Methylene blue seems to be a potent approach to refractory vasoplegia Nitric oxide is a mediator of systemic inflammatory response and is inhibited by methylene blue Useful when high doses of norepinephrine are required 1-2 mg/kg over 20”, 1 mg/kg/hr infusion Steroids?? Hydrocortisone 200 mg every 8 hours for vasoplegia May reduce catecholamine requirements Indicated only if adequate fluids and vasopressor use ineffective Lack of consistent evidence for outcomes Milrinone Useful if other receptors are down-regulated or desensitized (chronic heart failure) High utility with RV dysfunction Longer half-life (2 hours) than other inotropes Milrinone is an inodilator, and is used at 0.25-0.75 mcg/kg/minute Mild vasodilation occurs unless administered as a bolus (profound > 1 mg) Isoproterenol Profound beta-1 affinity, causing increased heart rate and contractility o Bradycardia not responsive to atropine o AV block, beta blocker overdose Binds to beta-2 receptors to produce vasodilation Used clinically for transplanted heart and electrophysiology for testing of re-entrant pathways Levosimendan Pharmacology Increased intracellular calcium may impair relaxation, increase MVO2 and ischemia Levoisimendan increases contractility and vasodilates o Increases troponin sensitivity to calcium o Activates adenosine triphosphate K+ channels causing vasodilation and myocardial protection o Cardiac output increased with decreased SVR and PVR Loading dose of 6–12 µg/kg over 10 minutes Continuous 24-hour infusion of 0.05–0.2 µg/kg/min Nicardipine Does not decrease myocardial contractility Mild suppression of automaticity and conduction Selective for vascular smooth muscle, especially coronary and cerebral Dose 50-200 mcg bolus, 1-15 mg/hour infusion Onset 2 minutes, half-life 40 minutes Clevidipine (Cleviprex) Ultra-short-acting (5”) Little or no effect on contractility or conduction Arterial only (no venous dilation or effect on filling volumes) Contraindicated in egg/soy allergies, aortic stenosis, HOCM Typical initial dosing is 1-2 mg/hour Epoprosterenol Potent peripheral vasodilator of all vascular beds; also prevents platelet aggregation Used primarily to decrease pulmonary vascular resistance without affecting SVR (inhaled) 50/ng/kg/min inhaled via nebulizer in circuit 2 ng/kg/min IV infusion
Recommended publications
  • Molecular Signatures of G-Protein-Coupled Receptors A

    Molecular Signatures of G-Protein-Coupled Receptors A

    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
  • Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression

    Emerging Evidence for a Central Epinephrine-Innervated A1- Adrenergic System That Regulates Behavioral Activation and Is Impaired in Depression

    Neuropsychopharmacology (2003) 28, 1387–1399 & 2003 Nature Publishing Group All rights reserved 0893-133X/03 $25.00 www.neuropsychopharmacology.org Perspective Emerging Evidence for a Central Epinephrine-Innervated a1- Adrenergic System that Regulates Behavioral Activation and is Impaired in Depression ,1 1 1 1 1 Eric A Stone* , Yan Lin , Helen Rosengarten , H Kenneth Kramer and David Quartermain 1Departments of Psychiatry and Neurology, New York University School of Medicine, New York, NY, USA Currently, most basic and clinical research on depression is focused on either central serotonergic, noradrenergic, or dopaminergic neurotransmission as affected by various etiological and predisposing factors. Recent evidence suggests that there is another system that consists of a subset of brain a1B-adrenoceptors innervated primarily by brain epinephrine (EPI) that potentially modulates the above three monoamine systems in parallel and plays a critical role in depression. The present review covers the evidence for this system and includes findings that brain a -adrenoceptors are instrumental in behavioral activation, are located near the major monoamine cell groups 1 or target areas, receive EPI as their neurotransmitter, are impaired or inhibited in depressed patients or after stress in animal models, and a are restored by a number of antidepressants. This ‘EPI- 1 system’ may therefore represent a new target system for this disorder. Neuropsychopharmacology (2003) 28, 1387–1399, advance online publication, 18 June 2003; doi:10.1038/sj.npp.1300222 Keywords: a1-adrenoceptors; epinephrine; motor activity; depression; inactivity INTRODUCTION monoaminergic systems. This new system appears to be impaired during stress and depression and thus may Depressive illness is currently believed to result from represent a new target for this disorder.
  • Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension

    Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension

    Reprinted from ANCIOLOCY Vol. 29, No. -I April 1978 Copyright 0 1978 Prinred in U.S.A. All Rights Rewrced Advantages and Disadvantages of Beta- Adrenergic Blocking Drugs in Hypertension Eoin T. O'Brien DUBLIN, IRELAND General Measures Elevation of blood pressure should be regarded as one of a number of potential risk factors for cardiovascular disease-albeit a major risk factor- rather than a disease per se.' It is important to identify additional risk factors in the hypertensive patient, not only because collectively these factors may greatly magnify the cardiovascular risk, but also because modification of them may, of itself, lower the blood pressure and thus alleviate the risk and save the patient the inconvenience, expense, and potential harm that may result from even the simplest of drug regimes. Careful consideration should be given to the patient's diet (particularly in relation to the calorie intake in the case of obesity, the cholesterol and saturated fat content in the case of hyperlipidemia and patients at high risk, and the salt content) and to smoking habits, physical activity. stress. personality, and drug therapy, especially anovulant preparations. Other diseases, such as diabetes mellitus, which are associated with a high incidence of hypertension and pri- mary causes of hypertension must be excluded. Although there is still no statistical evidence to show that modification of these risk factors-with the exception of tobacco and anovulant preparations-will actually reduce mortal- ity, it does seem prudent on the basis of the evidence available to encourage the hypertensive patient to adjust his or her life-style not only to reduce the cardiovascular risk,2 but also because in many instances the mildly hypertensive patient will respond to this approach alone.
  • Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents

    Drug Class Review Antianginal Agents 24:12.08 Nitrates and Nitrites 24:04.92 Cardiac Drugs, Miscellaneous Amyl Nitrite Isosorbide Dinitrate (IsoDitrate ER®, others) Isosorbide Mononitrate (Imdur®) Nitroglycerin (Minitran®, Nitrostat®, others) Ranolazine (Ranexa®) Final Report May 2015 Review prepared by: Melissa Archer, PharmD, Clinical Pharmacist Carin Steinvoort, PharmD, Clinical Pharmacist Gary Oderda, PharmD, MPH, Professor University of Utah College of Pharmacy Copyright © 2015 by University of Utah College of Pharmacy Salt Lake City, Utah. All rights reserved. Table of Contents Executive Summary ......................................................................................................................... 3 Introduction .................................................................................................................................... 4 Table 1. Antianginal Therapies .............................................................................................. 4 Table 2. Summary of Agents .................................................................................................. 5 Disease Overview ........................................................................................................................ 8 Table 3. Summary of Current Clinical Practice Guidelines .................................................... 9 Pharmacology ............................................................................................................................... 10 Table 4. Pharmacokinetic Properties
  • M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic

    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Defic

    M100907, a Serotonin 5-HT2A Receptor Antagonist and Putative Antipsychotic, Blocks Dizocilpine-Induced Prepulse Inhibition Deficits in Sprague–Dawley and Wistar Rats Geoffrey B. Varty, Ph.D., Vaishali P. Bakshi, Ph.D., and Mark A. Geyer, Ph.D. a In a recent study using Wistar rats, the serotonergic 5-HT2 1 receptor agonist cirazoline disrupts PPI. As risperidone a receptor antagonists ketanserin and risperidone reduced the and M100907 have affinity at the 1 receptor, a final study disruptive effects of the noncompetitive N-methyl-D- examined whether M100907 would block the effects of aspartate (NMDA) antagonist dizocilpine on prepulse cirazoline on PPI. Risperidone partially, but inhibition (PPI), suggesting that there is an interaction nonsignificantly, reduced the effects of dizocilpine in Wistar between serotonin and glutamate in the modulation of PPI. rats, although this effect was smaller than previously In contrast, studies using the noncompetitive NMDA reported. Consistent with previous studies, risperidone did antagonist phencyclidine (PCP) in Sprague–Dawley rats not alter the effects of dizocilpine in Sprague–Dawley rats. found no effect with 5-HT2 antagonists. To test the hypothesis Most importantly, M100907 pretreatment fully blocked the that strain differences might explain the discrepancy in effect of dizocilpine in both strains; whereas SDZ SER 082 these findings, risperidone was tested for its ability to had no effect. M100907 had no influence on PPI by itself reduce the PPI-disruptive effects of dizocilpine in Wistar and did not reduce the effects of cirazoline on PPI. These and Sprague–Dawley rats. Furthermore, to determine studies confirm the suggestion that serotonin and glutamate which serotonergic receptor subtype may mediate this effect, interact in modulating PPI and indicate that the 5-HT2A the 5-HT2A receptor antagonist M100907 (formerly MDL receptor subtype mediates this interaction.
  • Accelerated Resensitization of the D 1 Dopamine Receptor-Mediated

    Accelerated Resensitization of the D 1 Dopamine Receptor-Mediated

    The Journal of Neuroscience, October 1994, 74(10): 6260-6266 Accelerated Resensitization of the D 1 Dopamine Receptor-mediated Response in Cultured Cortical and Striatal Neurons from the Rat: Respective Role of CY1 -Adrenergic and /U-methybaspartate Receptors Fabrice Trovero, Philippe Marin, Jean-PO1 Tassin, JoQl Premont, and Jacques Glowinski INSERM U 114, Chaire de Neuropharmacologie, College de France, 75231 Paris Cedex, France As previously shown in vivo, noradrenergic and glutama- cortex. In the rat, bilateral electrolytic lesions of the mesence- tergic neurons can regulate the denervation supersensitivity phalic ventral tegmental area induce a complex and permanent of Dl dopaminergic (DA) receptors in the rat prefrontal cor- behavioral syndrome characterized by a locomotor hyperactiv- tex and striatum respectively. Therefore, the effects of meth- ity and the incapacity of the animal to focalize its attention (Le oxamine (an al-adrenergic agonist) and glutamate on the Moal et al., 1969). Some of the behavioral deficits observed in resensitization of Dl DA receptors were investigated in cul- the lesioned animals, particularly the locomotor hyperactivity, tured cortical and striatal neurons from the embryonic rat. have been attributed for a large part to the selective destruction In the presence of sulpiride and propranolol, DA stimulated of the cortical dopaminergic (DA) innervation (Tassin et al., the Dl DA receptor-mediated conversion of 3H-adenine into 1978). This locomotor hyperactivity was markedly reduced in 3H-cAMP in both intact cortical and striatal cells and these rats with 6-hydroxydopamine (6-OHDA) lesions,which destroy responses were markedly desensitized in cells preexposed not only the ascendingDA neurons but also the ascendingnor- for 15 min to DA (50 AM).
  • Covalent Agonists for Studying G Protein-Coupled Receptor Activation

    Covalent Agonists for Studying G Protein-Coupled Receptor Activation

    Covalent agonists for studying G protein-coupled receptor activation Dietmar Weicherta, Andrew C. Kruseb, Aashish Manglikb, Christine Hillera, Cheng Zhangb, Harald Hübnera, Brian K. Kobilkab,1, and Peter Gmeinera,1 aDepartment of Chemistry and Pharmacy, Friedrich Alexander University, 91052 Erlangen, Germany; and bDepartment of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, CA 94305 Contributed by Brian K. Kobilka, June 6, 2014 (sent for review April 21, 2014) Structural studies on G protein-coupled receptors (GPCRs) provide Disulfide-based cross-linking approaches (17, 18) offer important insights into the architecture and function of these the advantage that the covalent binding of disulfide-containing important drug targets. However, the crystallization of GPCRs in compounds is chemoselective for cysteine and enforced by the active states is particularly challenging, requiring the formation of affinity of the ligand-pharmacophore rather than by the elec- stable and conformationally homogeneous ligand-receptor com- trophilicity of the cross-linking function (19). We refer to the plexes. Native hormones, neurotransmitters, and synthetic ago- described ligands as covalent rather than irreversible agonists nists that bind with low affinity are ineffective at stabilizing an because cleavage may be promoted by reducing agents and the active state for crystallogenesis. To promote structural studies on disulfide transfer process is a reversible chemical reaction the pharmacologically highly relevant class
  • The Adrenergic Control of Lower Esophageal Sphincter Function: an EXPERIMENTAL MODEL of DENERVATION SUPERSENSITIVITY

    The Adrenergic Control of Lower Esophageal Sphincter Function: an EXPERIMENTAL MODEL of DENERVATION SUPERSENSITIVITY

    The Adrenergic Control of Lower Esophageal Sphincter Function: AN EXPERIMENTAL MODEL OF DENERVATION SUPERSENSITIVITY Anthony J. DiMarino, Sidney Cohen J Clin Invest. 1973;52(9):2264-2271. https://doi.org/10.1172/JCI107413. To evaluate the adrenergic regulation of lower esophageal sphincter (LES) function, LES pressure, LES relaxation during swallowing, and blood pressure were measured in the anesthetized opossum, Didelphis virginiana, during intravenous administration of alpha and beta adrenergic agonists and antagonists. Studies were done in controls and animals adrenergically denervated with 6-hydroxydopamine. Alpha adrenergic agonists (norepinephrine, phenylephrine) increased LES pressure and blood pressure, whereas a beta adrenergic agonist (isoproterenol) decreased both pressures. Alpha adrenergic antagonism (phentolamine) reduced basal LES pressure by 38.3±3.8% (mean ±SEM) (P < 0.001). Beta adrenergic antagonism (propranolol) had no significant effect on either basal LES pressure or percent of LES relaxation with swallowing. After adrenergic denervation with 6-hydroxydopamine, basal LES pressure was reduced by 22.5±5.3% (P < 0.025) but LES relaxation during swallowing was unaltered. In denervated animals, both LES pressure and blood pressure dose response curves showed characteristics of denervation supersensitivity to alpha but not to beta adrenergic agonists. These studies suggest: (a) a significant portion of basal LES pressure is dependent upon alpha adrenergic stimulation; (b) LES relaxation during swallowing is not an adrenergically mediated response; c( ) the LES pressure response to alpha adrenergic agonists after 6-hydroxydopamine may serve as a model of denervation supersensitivity in the gastrointestinal tract. Find the latest version: https://jci.me/107413/pdf The Adrenergic Control of Lower Esophageal Sphincter Function AN EXPERIMENTAL MODEL OF DENERVATION SUPERSENSITIVITY ANTHoNY J.
  • COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Review – October 2020 Page 2 | Proprietary Information

    COPD Agents Therapeutic Class Review (TCR) October 1, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. October 2020
  • Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review

    Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: a Literature Review

    medical sciences Review Pharmacological Approach to Sleep Disturbances in Autism Spectrum Disorders with Psychiatric Comorbidities: A Literature Review Sachin Relia 1,* and Vijayabharathi Ekambaram 2,* 1 Department of Psychiatry, University of Tennessee Health Sciences Center, 920, Madison Avenue, Suite 200, Memphis, TN 38105, USA 2 Department of Psychiatry, University of Oklahoma Health Sciences Center, 920, Stanton L Young Blvd, Oklahoma City, OK 73104, USA * Correspondence: [email protected] (S.R.); [email protected] (V.E.); Tel.: +1-901-448-4266 (S.R.); +1-405-271-5251 (V.E.); Fax: +1-901-297-6337 (S.R.); +1-405-271-3808 (V.E.) Received: 15 August 2018; Accepted: 17 October 2018; Published: 25 October 2018 Abstract: Autism is a developmental disability that can cause significant emotional, social and behavioral dysfunction. Sleep disorders co-occur in approximately half of the patients with autism spectrum disorder (ASD). Sleep problems in individuals with ASD have also been associated with poor social interaction, increased stereotypy, problems in communication, and overall autistic behavior. Behavioral interventions are considered a primary modality of treatment. There is limited evidence for psychopharmacological treatments in autism; however, these are frequently prescribed. Melatonin, antipsychotics, antidepressants, and α agonists have generally been used with melatonin, having a relatively large body of evidence. Further research and information are needed to guide and individualize treatment for this population group. Keywords: autism spectrum disorder; sleep disorders in ASD; medications for sleep disorders in ASD; comorbidities in ASD 1. Introduction Autism is a developmental disability that can cause significant emotional, social, and behavioral dysfunction. According to the Diagnostic and Statistical Manual (DSM-V) classification [1], autism spectrum disorder (ASD) is characterized by persistent deficits in domains of social communication, social interaction, restricted and repetitive patterns of behavior, interests, or activities.
  • Original Research Bethanecol Chloride for Treatment of Clomipramine

    Original Research Bethanecol Chloride for Treatment of Clomipramine

    REV. HOSP. CLÍN. FAC. MED. S. PAULO 59(6):357-360, 2004 ORIGINAL RESEARCH BETHANECOL CHLORIDE FOR TREATMENT OF CLOMIPRAMINE-INDUCED ORGASMIC DYSFUNCTION IN MALES Márcio Bernik, Antonio Hélio Guerra Vieira and Paula Villela Nunes BERNIK M et al. Bethanecol chloride for treatment of clomipramine-induced orgasmic dysfunction in males. Rev. Hosp. Clin. Fac. Med. S. Paulo 59(6):357-360, 2004. PURPOSE: To investigate whether bethanecol chloride may be an alternative for the clinical management of clomipramine-induced orgasmic dysfunction, reported to occur in up to 96% of male users. METHODS: In this study, 12 fully remitted panic disorder patients, complaining of severe clomipramine-induced ejaculatory delay, were randomly assigned to either bethanecol chloride tablets (20 mg, as needed) or placebo in a randomized, double-blind, placebo-controlled, two-period crossover study. A visual analog scale was used to assess severity of the orgasmic dysfunction. RESULTS: A clear improvement was observed in the active treatment period. No placebo or carry-over effects were observed. CONCLUSION: These findings suggest that bethanecol chloride given 45 minutes before sexual intercourse may be useful for clomipramine-induced orgasmic dysfunction in males. KEYWORDS: Orgasmic dysfunction. Clomipramine. Bethanecol chloride. Panic disorder. Pharmacological treatment. In panic disorder patients, effective clude the following: 1) increased brain side effects such as orgasmic dysfunc- pharmacological treatment with anti- serotonin, particularly affecting 5TH2 tion in up to 20% to 96% of pa- depressants has been shown to greatly and 5HT3 receptors; 2) decreased tients.5,6,13 improve the quality of life, but it is of- dopamine; 3) central blockade of Clomipramine is the imipramine ten associated with the emergence of cholinergic and alpha-1 adrenergic analogue of chlorpromazine.
  • Age-Associated Reductions in Cardiac Beta1- and Beta2- Adrenergic Responses Without Changes in Inhibitory G Proteins Or Receptor Kinases

    Age-Associated Reductions in Cardiac Beta1- and Beta2- Adrenergic Responses Without Changes in Inhibitory G Proteins Or Receptor Kinases

    Age-associated reductions in cardiac beta1- and beta2- adrenergic responses without changes in inhibitory G proteins or receptor kinases. R P Xiao, … , E G Lakatta, W J Koch J Clin Invest. 1998;101(6):1273-1282. https://doi.org/10.1172/JCI1335. Research Article While an age-associated diminution in myocardial contractile response to beta-adrenergic receptor (beta-AR) stimulation has been widely demonstrated to occur in the context of increased levels of plasma catecholamines, some critical mechanisms that govern beta-AR signaling must still be examined in aged hearts. Specifically, the contribution of beta- AR subtypes (beta1 versus beta2) to the overall reduction in contractile response with aging is unknown. Additionally, whether G protein-coupled receptor kinases (GRKs), which mediate receptor desensitization, or adenylyl cyclase inhibitory G proteins (Gi) are increased with aging has not been examined. Both these inhibitory mechanisms are upregulated in chronic heart failure, a condition also associated with diminished beta-AR responsiveness and increased circulatory catecholamines. In this study, the contractile responses to both beta1-AR and beta2-AR stimulation were examined in rat ventricular myocytes of a broad age range (2, 8, and 24 mo). A marked age-associated depression in contractile response to both beta-AR subtype stimulation was observed. This was associated with a nonselective reduction in the density of both beta-AR subtypes and a reduction in membrane adenylyl cyclase response to both beta- AR subtype agonists, NaF or forskolin. However, the age-associated diminutions in contractile responses to either beta1- AR or beta2-AR stimulation were not rescued by inhibiting Gi with pertussis toxin treatment.